The efficacy of PD‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study
Sign Up to like & getrecommendations! Published in 2022 at "Laryngoscope Investigative Otolaryngology"
DOI: 10.1002/lio2.863
Abstract: Immune checkpoint inhibitors (ICIs) have been considered as novel therapeutic approaches for various cancers. ICIs were reportedly efficacious against rare cancers, including salivary gland carcinoma (SGC). We aimed to analyze the efficacy and safety of… read more here.
Keywords: gland carcinoma; efficacy inhibitors; salivary gland;
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02889-0
Abstract: PurposeWe evaluated the predictive role of EGFR mutation on the efficacy of PD-1/PD-L1 inhibitor therapy in patients with advanced pulmonary adenocarcinoma while considering clinical factors such as PD-L1 expression, gender, and smoking status.MethodsPatients were required… read more here.
Keywords: egfr mutation; efficacy inhibitors; expression; pulmonary adenocarcinoma ... See more keywords
Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?
Sign Up to like & getrecommendations! Published in 2022 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2022.108738
Abstract: Although PD-1/PD-L1 inhibitors are widely used as first-line treatment for patients with advanced tumors or as adjuvant therapy for patients with early-stage tumors, their efficacy is only 15-60%. Increasing evidence has demonstrated that biomarkers such… read more here.
Keywords: efficacy inhibitors; efficacy; related adverse; adverse events ... See more keywords
Efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced non‐small cell lung cancer: A meta‐analysis of randomized clinical trials
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13060
Abstract: This meta‐analysis systematically evaluated the efficacy of PD‐1 and PD‐L1 inhibitors for the treatment of advanced non‐small cell lung cancer (NSCLC) and investigated the efficacy of first‐line therapy and PD‐1 versus PD‐L1 inhibitors. read more here.
Keywords: advanced non; efficacy inhibitors; non small; cancer ... See more keywords
Single institution experience looking at efficacy of PD-1 inhibitors after progression on PD-L1 inhibitors or vice-versa in metastatic non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21726
Abstract: e21726Background: The treatment landscape for metastatic NSCLC has changed dramatically with emergence of checkpoint inhibitors (CPI). Even though all currently approved CPI target engagement of PD... read more here.
Keywords: looking efficacy; institution experience; efficacy inhibitors; inhibitors progression ... See more keywords
Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0305
Abstract: Objective: Evaluate the potency of anti-PD-1/PD-L1 antibodies in advanced gastroesophageal cancer patients with different clinical features. Methods: Randomized, controlled trials comparing anti-PD-1/PD-L1 antibodies with chemotherapy in individuals with gastroesophageal cancer were retrieved. Results: 15 trials involving… read more here.
Keywords: gastroesophageal cancer; efficacy inhibitors; inhibitors advanced; analysis ... See more keywords
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.893179
Abstract: Background Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients… read more here.
Keywords: preexisting autoantibodies; anti ro52; efficacy inhibitors; safety efficacy ... See more keywords
Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29050238
Abstract: In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1… read more here.
Keywords: combination chemoradiotherapy; efficacy inhibitors; chemoradiotherapy chemotherapy; inhibitors combination ... See more keywords